Evidence map›Paper›PMID 41507805›Full record

ArticleBMC infectious diseases2026

Clinical characteristics of pregnant patients with rifampicin-resistant tuberculosis: a retrospective analysis.

Ning Luo, Min Lai, Shenjie Tang, Guihui Wu, Hongde Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ning Luo *Department VI of Tuberculosis, Public Health Clinical Center of Chengdu, Chengdu, 610061, China.
Min Lai *Department VI of Tuberculosis, Public Health Clinical Center of Chengdu, Chengdu, 610061, China.
Shenjie TangBeijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, 101149, China.
Guihui WuDepartment IV of Tuberculosis, Public Health Clinical Center of Chengdu, Chengdu, 610061, China.
Hongde ChenDepartment VI of Tuberculosis, Public Health Clinical Center of Chengdu, Chengdu, 610061, China. 675544098@qq.com.

Funding

Medical Research Project Plan of Sichuan Province, A Study on the Efficacy and Safety of a Fully Oral Regimen Containing Bedaquiline and Linezolid for the Treatment of Multidrug-Resistant Tuberculosis S22042
6 · The paper itself

Abstract

backgroundResearch on pregnant patients with rifampicin-resistant tuberculosis remains limited. This study aims to retrospectively analyze the clinical characteristics and outcomes of pregnant patients with rifampicin-resistant tuberculosis, providing valuable insights for the management and treatment of such cases.

methodsThis retrospective study reviewed the electronic medical records of pregnant patients with rifampicin-resistant tuberculosis admitted to the Public Health Clinical Center of Chengdu between July 2017 and April 2025. The clinical characteristics and outcomes of these patients were analyzed.

resultsA total of 21 pregnant patients with rifampicin-resistant tuberculosis were included in the study, with a mean age of 28.8 years. Among them, 14 patients (66.7%) had no prior history of tuberculosis treatment, and 18 patients (85.7%) conceived naturally. The majority (90.5%) were carrying a singleton pregnancy. Regarding treatment outcomes (referring to maternal tuberculosis treatment outcomes), 11 patients (52.4%) were cured, 8 patients (38.1%) completed treatment, and 2 patients (9.5%) died. Adverse reactions occurred in 12 patients (57.1%) during treatment. Pregnancy outcomes (two twins) included 6 live births (26.1%), 5 miscarriages (21.7%), 1 died (4.3%) and 11 pregnancy terminations (47.8%).

conclusionThe findings suggest that pregnant patients with rifampicin-resistant tuberculosis can achieve favorable maternal treatment outcomes with appropriate treatment. However, nearly half of the patients (52.4%) opted for pregnancy termination.

Indexed as

Antitubercular AgentsPregnancy Complications, InfectiousRifampinTuberculosis, Multidrug-ResistantAdultFemaleHumansMycobacterium tuberculosisPregnancyPregnancy OutcomeRetrospective StudiesTreatment OutcomeYoung AdultAntitubercular AgentsRifampinClinical outcomesPregnant patientsRifampicin-resistant tuberculosis

Identifiers

PMID41507805
PMCPMC12874924

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.